TB Guidelines

Treatment

 

Treatment Guidelines
 Title Format Date Published
MMWR /Medscape free CE credit on the updated 2020 latent TB infection treatment guidelines.external icon
Registration may be required.
2/20/2020
Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020
MMWR Recomm Rep 2020; 69(No. RR-1): 1-11.
PDFpdf icon (337 KB) 2/20/2020
Treatment of Drug-Resistant Tuberculosis
American Journal of Respiratory and Critical Care Medicine, 2019
Full Guidelinesexternal icon
Executive Summary
PDFpdf icon  (731 KB)Full Guidelines
PDFpdf icon (1 MB)
9/1/2019
Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection
MMWR 2018;67:723-726
PDFpdf icon
(94 KB)
6/1/2018
Treatment of Drug-Susceptible Tuberculosis
Executive Summaryexternal icon
Full Guidelinesexternal icon
Clinical Infectious Disease 2016
PDFpdf icon
(1 MB)
8/1/2016
Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis
MMWR  2013;62 (No. 9)
PDFpdf icon
(411 KB)
10/1/2013
Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis
June 2013
PDFpdf icon
(492 KB)
6/1/2013
Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis: Recommendations from the National Tuberculosis Controllers Association and CDC
MMWR  2005; 54 (No. RR-15, 1-37)
PDFpdf icon
(544 KB)
12/1/2005
Treating Opportunistic Infections Among HIV-Exposed and Infected Children
MMWR 2004; 53 (RR14)
PDFpdf icon
(742 KB)
12/1/2004
Tuberculosis Associated with Blocking Agents Against Tumor Necrosis Factor – Alpha – California, 2002–2003
MMWR  2004; 53 (No. 30)
PDFpdf icon
(325 KB)
12/1/2004
Notice to Readers: Updated Guidelines for the Use of Rifamycins for the Treatment of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors
MMWR  2004; 53 (No. 2)
PDFpdf iconpdf icon
(349 KB)
1/1/2004
Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection
MMWR  2003; 52 (No. 31).
PDFpdf icon
(587 MB)
8/1/2003